atHeart Medical news

French TV France3 reported on the first patients implanted with a reSept ASD Occluder in France and in the European Union at Bordeaux University Hospital. The coverage includes video interviews with young patient Léo and his mother, and with the doctors that treated him, as part of the ASCENT ASD trial.

Professor Jean-Benoît Thambo, head of the department of pediatric and congenital cardiology at the Bordeaux University Hospital, said to France3 how “these prosthese

atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced it has received approval for the start of the second phase of its ASCENT ASD U.S. Investigational Device Exemption (IDE) pivotal trial.

The prospective, single-arm study is evaluating the safety and efficacy of the reSept™ ASD Occluder, the first occluder with a metal-free, bioresorbable frame, for the treatment of patients with

atHeart Medical has received approval for the start of the second phase of its ASCENT ASD U.S. Investigational Device Exemption (IDE) pivotal trial.

The prospective, single-arm study is evaluating the safety and efficacy of the reSept^™ ASD Occluder, the first occluder with a metal-free, bioresorbable frame, for the treatment of patients with clinically significant, isolated ASDs. Primary endpoints will be compared with established performance goals f

The story of the first patient implanted with a reSept ASD Occluder in Switzerland has been reported in Forschungs-Magazin, the research magazine by Children’s Hospital Zurich, where Mathilda’s intervention took place.

In a heartfelt recollection, Mathilda’s family shared their journey from diagnosis, through to coronavirus and travel restrictions, to the operation with a novel device with a metal-free frame, and the welcomed, normal life t